Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Other hematologic neoplasm 2Other neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cytarabine 116Cyclophosphamide 104venetoclax 89fludarabine 85Azacitidine 81fludarabine phosphate 70Rituximab 59Filgrastim 44Peripheral Blood Stem Cell Transplantation 39Methotrexate 39Dexamethasone 35Decitabine 35Busulfan 32Etoposide 31Tacrolimus 30Mycophenolic Acid 29Granulocyte Colony-Stimulating Factor 28Lenalidomide 27Whole-Body Irradiation 26Idarubicin 26Vincristine 25Melphalan 24Cyclosporine 24Clofarabine 24Mitoxantrone 22Bortezomib 21Alemtuzumab 21ibrutinib 19ruxolitinib 17aldesleukin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Infusions, Intravenous × Other hematologic neoplasm × Clear all
NCT03850574 2025-08-26

TUSCANY

Aptose Biosciences Inc.

Phase 1/2 Recruiting
240 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05448599 2023-03-15

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2 Unknown
120 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡